- Home
- ACRS vs MYFW Comparison
ACRS vs MYFW Comparison
Compare ACRS & MYFW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACRS | MYFW |
|---|---|---|
| Founded | 2012 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 311.0M | 256.7M |
| IPO Year | 2015 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ACRS | MYFW |
|---|---|---|
| Price | $4.98 | $28.55 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 1 |
| Target Price | $10.20 | ★ $27.00 |
| AVG Volume (30 Days) | ★ 1.3M | 24.9K |
| Earning Date | 05-07-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.01 | 54.02 |
| EPS | N/A | ★ 0.63 |
| Revenue | $1,683,000.00 | ★ $96,914,000.00 |
| Revenue This Year | N/A | $20.48 |
| Revenue Next Year | $4.24 | $9.70 |
| P/E Ratio | ★ N/A | $45.64 |
| Revenue Growth | N/A | ★ 7.60 |
| 52 Week Low | $1.22 | $20.11 |
| 52 Week High | $5.12 | $30.00 |
Technical Indicators
Market Signals| Indicator | ACRS | MYFW |
|---|---|---|
| Relative Strength Index (RSI) | 66.69 | 58.93 |
| Support Level | $2.67 | $21.83 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.27 | 1.13 |
| MACD | 0.03 | -0.05 |
| Stochastic Oscillator | 86.45 | 59.71 |
Price Performance
Historical ComparisonAbout ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About MYFW First Western Financial Inc.
First Western Financial Inc is a financial holding company that provides a fully integrated suite of wealth management services on its private trust bank platform, which includes a comprehensive selection of deposit, loan, trust, wealth planning, and investment management products and services. The company has two operating segments; The Wealth Management segment consists of operations relative to the Company's fully integrated wealth management products and services, and The Mortgage segment consists of operations relative to the Company's residential mortgage service offerings. The bank derives its majority revenue from the wealth management segment.